Lassa fever vaccine study for people in West Africa
Part of Infections clinical trials.
This trial tests an investigational vaccine to prevent Lassa fever, a serious illness found in parts of West Africa. People in different age groups will get the vaccine or a placebo and be followed to see if it’s safe and helps the immune system respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 months and 70 years old on the right study day (age rules differ by group).
- Be generally healthy based on medical history, exam, and blood/urine test results.
- Be willing and able to come to study visits and stay for the planned follow-up time.
- Agree to HIV testing, receive results, and take HIV risk-reduction counseling if asked at the required times.
- Follow study pregnancy prevention rules: use effective contraception and do pregnancy tests at scheduled times; also use condoms if sexually active.
- Do not get certain other vaccines, blood transfusions, or join another study during the allowed time windows before/after the trial vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of antiviral drugs (favipiravir, ribavirin, and a steroid called dexamethasone) in adults hospitalized with Lassa fever. The goal is to find the safest and most effective treatment.
This trial tests whether adding dexamethasone, a steroid that reduces inflammation, to standard care can help people with severe Lassa fever. It is for adults who are very sick with confirmed Lassa fever.
This trial tests a way to give HPV vaccines along with routine childhood immunizations in Ghana. It aims to protect against HPV, a virus that can cause cervical cancer, by making it easier to get the vaccine.
This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults. Participants will receive the vaccine and then be exposed to malaria to see if it protects them.
This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults living in Burkina Faso. If you qualify, the vaccine is given to see if it can protect you from malaria.
This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.
Hear when a new Lassa Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.